Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients With Advanced Tumors and Lymphomas
Conditions
Interventions
CA-170
Locations
20
United States
University of California San Francisco
San Francisco, California, United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Sarah Cannon Research Institute
Sarasota, Florida, United States
Northwestern University
Chicago, Illinois, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Icahn School of Medicine at Mt. Sinai
New York, New York, United States
Start Date
May 1, 2016
Primary Completion Date
May 7, 2020
Completion Date
May 7, 2020
Last Updated
June 26, 2020
Lead Sponsor
Curis, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions